Prime Medicine, Inc. EBITDA

EBITDA of PRME for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.

Highlights and Quick Summary

  • EBITDA for the quarter ending September 30, 2023 was $-47.1 Million (a 15.79% increase compared to previous quarter)
  • Year-over-year quarterly EBITDA increased by 34.47%
  • Annual EBITDA for 2022 was $-105 Million (a 31.3% increase from previous year)
  • Annual EBITDA for 2021 was $-79.6 Million (a 8855.34% increase from previous year)
  • Annual EBITDA for 2020 was $-889 Thousand (a -59.07% decrease from previous year)
  • Twelve month EBITDA ending September 30, 2023 was $-159 Million (a 13.44% increase compared to previous quarter)
  • Twelve month trailing EBITDA increased by 46.47% year-over-year
Trailing EBITDA for the last four month:
30 Sep '23 30 Jun '23 31 Mar '23 31 Dec '22
$-159 Million $-140 Million $-125 Million $-109 Million
Visit stockrow.com/PRME for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of Prime Medicine, Inc.

Most recent EBITDAof PRME including historical data for past 10 years.

Interactive Chart of EBITDA of Prime Medicine, Inc.

Prime Medicine, Inc. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2023 $-47.09 $-40.67 $-36.15 – –
2022 $-35.02 $-28.25 $-25.82 $-19.41 $-104.53
2021 – – – $-10.43 $-79.61
2020 – – – – $-0.89
2019 – – – – $-2.17

Business Profile of Prime Medicine, Inc.

Sector: Healthcare
Industry: Biotechnology
© stockrow.com